The dramatic restructuring plan disclosed earlier this week by Biogen Idec Inc. has the Weston, Mass.-based firm clearing out of the cardiovascular space altogether, a move that leaves Cardiokine Inc. flying solo on hyponatremia drug lixivaptan. (BioWorld Today) Read More